PT-141

• The defensible B2B value is a form-defined analytical or research material for melanocortin-receptor assays, ligand-binding and signalling studies, identity and impurity method development, formulation compatibility and controlled preclinical models
• Pivotal trials support only the labelled finished drug and population, with modest absolute efficacy differences and substantial nausea
• Early male or intranasal studies do not create an approved indication or a claim for this SKU.

CAS

189691-06-3

Formula

C₅₀H₆₈N₁₄O₁₀ (free base)

Molecular weight

approximately 1025.2 g/mol

Appearance

White to off-white lyophilized powder

Purity

≥ 99.0% · target, verify batch COA

Storage

Follow lot-specific stability data for the declared free-base or acetate material. Protect from light and moisture and verify temperature-excursion, oxidation, deamidation, hydrolysis, adsorption and aggregate controls. The room-temperature instruction for Vyleesi's formulated prefilled autoinjector cannot establish storage or solution hold time for a lyophilized RUO vial.

MOQ

On request

Lead time

10–18 days

Bremelanotide is a synthetic N-acetylated cyclic heptapeptide melanocortin-receptor agonist related to alpha-MSH analogues. FDA approved Vyleesi, a defined bremelanotide-acetate injection, in 2019 for a limited acquired, generalized HSDD population. That approval applies to the sponsor's finished formulation and device; it does not approve generic PT-141 powder, male use, performance enhancement or other routes. The RUO page therefore uses the label as evidence context and identity support, not as administration guidance.

• Appropriate work includes receptor-binding and functional signalling assays, structure-activity research, cyclic-peptide identity and stereochemical methods, free-base/acetate equivalence, impurity and degradation profiling, formulation compatibility and controlled preclinical models
• HSDD treatment is an indication of Vyleesi only; male erectile dysfunction, postmenopausal use, sexual-performance enhancement, appetite effects and self-injection are not approved or validated uses of this SKU.

Bremelanotide is a melanocortin-receptor agonist with activity at multiple receptor subtypes. The current FDA label states that the mechanism by which it improves HSDD is unknown. MC4R-centred hypotheses and neuroimaging findings can guide research, but they do not establish single-receptor selectivity, eliminate MC1R-related pigmentation risk or prove a complete central signalling pathway.

• This RUO material has no human safety qualification
• The approved Vyleesi label includes transient blood-pressure increases and heart-rate reduction, contraindications for uncontrolled hypertension or known cardiovascular disease, focal hyperpigmentation that may not resolve, nausea, flushing, injection-site reactions, headache and vomiting, plus reproductive-use limitations
• Those risks contradict claims that PT-141 has no cardiovascular or pigmentation effects
• Chemical purity cannot establish sterile-drug safety, and this vial must not be used as a substitute for the prescription product.

Interactions reported in the literature

• In finished-product labelling, bremelanotide may slow gastric emptying and alter absorption of oral medicines, and can significantly reduce systemic exposure to orally administered naltrexone
• These are clinical label facts, not combination instructions for RUO powder
• For laboratory work, evaluate buffer, pH, counterion, surfaces, proteases, oxidants and receptor-assay controls; no validated compatibility matrix exists for mixing this material with PDE5 inhibitors, melanocortin analogues, hormones or other peptides.

PT-14110 mg · WHJLP-PT10-260525-D

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

• The COA must state free base versus acetate, acetate stoichiometry and assay on a free-base or as-is basis
• Require high-resolution intact mass, MS/MS or mapping, sequence and ring-closure confirmation, D-Phe stereochemical control, N-terminal acetylation, C-terminal free acid, chromatographic purity and identified impurity profile, peptide content, acetate, water, residual solvents, elemental impurities, counterion and mass balance, plus lot stability
• If a buyer needs bioburden or endotoxin limits for a non-administration assay, they must be specified separately; neither test establishes sterility or human-use suitability.

Follow lot-specific stability data for the declared free-base or acetate material. Protect from light and moisture and verify temperature-excursion, oxidation, deamidation, hydrolysis, adsorption and aggregate controls. The room-temperature instruction for Vyleesi's formulated prefilled autoinjector cannot establish storage or solution hold time for a lyophilized RUO vial.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

• Current DailyMed labelling distinguishes bremelanotide acetate in the Vyleesi finished product from free-base molecular mass and states that the clinical mechanism is unknown. PubChem CID 9941379 supports free-base identity, formula and CAS 189691-06-3. The FDA approval package and multidisciplinary review define the limited approved indication and benefit-risk basis. Kingsberg 2019 reports the pivotal trials; Simon 2019 is an open-label extension with substantial attrition; subgroup and neuroimaging analyses remain secondary or mechanistic. No source converts Vyleesi approval into approval of this RUO powder.

1. 01

   Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

   Obstetrics & Gynecology · 2019 · peer-reviewed original research (pivotal RECONNECT phase 3 RCTs)

   Open source
2. 02

   Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

   Obstetrics & Gynecology · 2019 · peer-reviewed original research (52-week open-label extension study)

   Open source
3. 03

   Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide

   Journal of Women's Health (Larchmont) · 2022 · peer-reviewed original research (integrated post-hoc subgroup analysis of pivotal trials)

   Open source
4. 04

   Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder

   The Journal of Clinical Investigation · 2022 · peer-reviewed original research (randomized, double-blind, placebo-controlled crossover neuroimaging study)

   Open source
5. 05

   VYLEESI (bremelanotide injection) Prescribing Information

   DailyMed · 2025 · current U.S. prescription-drug label

   Open source
6. 06

   Vyleesi NDA 210557 Approval Package

   FDA Drugs@FDA · 2019 · U.S. government approval record

   Open source
7. 07

   Vyleesi Multi-Discipline Review and Evaluation

   FDA Center for Drug Evaluation and Research · 2019 · U.S. government scientific benefit-risk review

   Open source
8. 08

   PubChem Compound Summary: Bremelanotide

   PubChem · 2026 · authoritative chemical identity database

   Open source